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Abstract: The purpose of this study was to compare the efficacy of botulinum toxin (BoNT) in
masseter muscle reduction depending on the amount of chin deviation. Exploring distinctive effects of
BoNT relative to the characteristics of facial asymmetry will aid in planning and predicting treatment
outcomes. Sixteen adult volunteers were classified into two groups according to the degree of menton
deviation observed in posteroanterior cephalograms. Eight had a menton deviation of 3 mm or
more and the other eight had less than 3 mm. A total of 25 Units of BoNT was injected into the
unilateral masseter muscle of the prominent side for each participant. Changes in the volume and
bulkiest height of the lower face on each side were measured with a 3D laser scan at four time points:
before and 4, 8, and 12 weeks after the injection. Two-way mixed ANOVA was employed for analyses.
The volume and bulkiest height of the injected side decreased over time in both types of asymmetry,
with significant differences at each time point. The reductions in the volume and bulkiest height were
significantly greater in subjects without chin deviation. The reductions in the volume and bulkiest
height of the lower face using BoNT are more effective for subjects without chin deviation.
Keywords: botulinum toxins; asymmetry; posteroanterior (PA) cephalometrics
Key Contribution: The efficacy of botulinum neurotoxin (BoNT) injection into masseter muscle
differed based on the amount of chin deviation; a critical element of facial asymmetry. The reductions
in the volume and bulkiest height of the lower face using BoNT are more effective for subjects without
chin deviation.
1. Introduction
There has been growing demand for the correction of facial asymmetry as patient expectations
have increased [1]. Disharmony of lower facial width is a type of facial asymmetry whose mainstay
corrective surgical procedures include orthognathic surgery, resection of the corresponding portion
of the mandible, and resection of the masseter muscle [1,2]. Meanwhile, patients tend to prefer less
invasive options, such as botulinum neurotoxin (BoNT) injection into masseter muscle to reduce its
volume [3].
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The BoNT is produced by Clostridium botulinum and consists of a heavy chain and a light chain
linked together by a single disulphide bond [4]. It is synthesised as a relatively inactive single-chain
polypeptide approximately 150 kDa, and is activated when proteolytically cleaved into the 100-kDa
heavy chain and the 50-kDa light chain [5]. While BoNT exists in seven different serotypes, named A,
B, C, D, E, F and G, type A has been the most widely used for therapeutic purposes. The BoNT
permanently binds to the motor end plate at the neuromuscular junction which prevents the release of
acetylcholine from the pre-synaptic vesicles causing a pre-synaptic blockade [3].
BoNT injection is a meritorious method for improving facial esthetics. The chemodenervation,
via BoNT injection, can improve facial wrinkles and reduce the width of the lower face by means of
masstere muscle atrophy [6]. Due to its synergestic effects, it has been applied to various procedures
aimed at enhancing facial esthetics [6]. The first report of BoNT for masseter muscle hypertrophy was
in 1994. Local injection of BoNT into a muscle produces paralysis and atrophy [7]. Side effects and
possible reactions of BoNT injection into masseter muscle are minor, including temporary paralysis of
adjacent facial muscles, soreness and swelling at the injection site, which resolves within 2 weeks [8].
As precisely predicting the post-treatment outcome in facial asymmetry remains challenging,
given the diverse patterns of asymmetry and the involvement of both skeletal and soft tissue changes,
the asymmetry can remain after the corrective surgery [1,2,9]. BoNT can be utilized as an adjunct
procedure in such cases. However, the efficacy of BoNT may vary according to the character and
severity of the asymmetry.
The purpose of this study was to compare the efficacy of BoNT injection into masseter muscle
depending on the amount of chin deviation, a critical element in the perception of facial asymmetry [10].
2. Results
2.1. Demographic Data
There was no statistically significant difference between the demographic data of the two groups
other than the amount of menton deviation (Table 1).
Table 1. Demographic data of the subjects.
Variables
Deviated Chin Non-Deviated Chin
p
(n = 8) (n = 8)
Age [IQR] 25.0 [22.0; 33.0] 26.5 [25.0; 34.0] 0.311 Mann–Whitney U test
Sex 1.000 Fisher’s Exact Test
Female 5 (62.5%) 6 (75.0%)
Male 3 (37.5%) 2 (25.0%)
Menton deviation (mean ± SD) 5.4 ± 1.2 1.5 ± 0.9 0.002 t-test
IQR: Interquartile range, SD: Standard deviation.
2.2. Summary Statistics
The means and standard deviations of the height and volume change compared to the pre-injection
state at each time point were acquired (Table 2).
Table 2. Mean change in the volume and bulkiest height of the lower face at each time point. A minus
sign indicates a reduction in measurement.
BoNT
Injection
Time after BoNT Injection






control −76 (551) 112 (1105) −59 (660)
injected −1015 (561) −1364 (715) −1389 (735)
Group II
non-deviated chin
control −572 (679) −180 (566) −323 (691)






control −0.14 (0.44) −0.09 (0.7) 0.03 (0.49)
injected −1.22 (0.55) −1.62 (0.74) −1.66 (0.48)
Group II
non-deviated chin
control −0.56 (0.51) −0.53 (0.44) −0.58 (0.59)
injected −2.45 (1.06) −3.26 (1.09) −3.70 (0.74)
BoNT: Botulinum toxin, SD: Standard deviation.
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2.3. Assumption Check
The height and volume change were normally distributed for each combination of factor levels
as assessed by Shapiro–Wilk’s test of normality (p > 0.05). There was homogeneity of variances as
assessed by Levene’s test (p > 0.05). The homogeneity of covariances was present as assessed by Box’s
test of equality of covariance matrices (p > 0.001).
2.4. Report
There was a statistically significant two-way interaction between the groups and time in
explaining both the volume and height change. Volume: F (6, 56) = 4.835, p < 0.001 (Figure 1).
Height: F (6, 56) = 4.505, p < 0.001 (Figure 2).
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2.5. Post-Hoc Tests
In terms of volume change, the simple main effect of the groups was significant at all time points
considering the Bonferroni-adjusted p-value (p < 0.0001) (Table 3). This was also the case in the bulkiest
height change.
Table 3. Effect of group in bulkiest height and volume change at each time point. ANOVA.
Change Time Effect Bonferroni-Adjusted p-Value
Volume change
4 weeks Group 3.00 × 10−3 **
8 weeks Group 7.20 × 10−5 ****
12 weeks Group 7.46 × 10−8 ****
Bulkiest height change
4 weeks Group 4.71 × 10−6 ****
8 weeks Group 7.65 × 10−8 ****
12 weeks Group 4.32 × 10−12 ****
(* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Pairwise comparisons show that the mean volume change was significantly different between the
control side and injected side for each group of chin deviation at 8 and 12 weeks. The comparison
within injected sides between deviated and non-deviated chin groups revealed statistically significant
differences at 12 weeks (Table 4).
Table 4. Pairwise comparisons between group levels for volume change. Pairwise t-test.
Time Group1 Group2 Bonferroni-Adjusted p-Value
4 weeks deviated-control nondeviated-control 1.00
4 weeks deviated-control deviated-injected 1.24 × 10−1
4 weeks deviated-control nondeviated-injected 7.34 × 10−4 ***
4 weeks nondeviated-control deviated-injected 1.00
4 weeks nondeviated-control nondeviated-injected 2.26 × 10−2 *
4 weeks deviated-injected nondeviated-injected 3.29 × 10−1
8 weeks deviated-control nondeviated-control 1.00
8 weeks deviated-control deviated-injected 1.40 × 10−2 *
8 weeks deviated-control nondeviated-injected 5.67 × 10−5 ****
8 weeks nondeviated-control deviated-injected 7.21 × 10−2
8 weeks nondeviated-control nondeviated-injected 3.45 × 10−4 ***
8 weeks deviated-injected nondeviated-injected 3.01 × 10−1
12 weeks deviated-control nondeviated-control 1.00
12 weeks deviated-control deviated-injected 1.21 × 10−2 *
12 weeks deviated-control nondeviated-injected 4.29 × 10−8 ****
12 weeks nondeviated-control deviated-injected 6.51 × 10−2
12 weeks nondeviated-control nondeviated-injected 2.32 × 10−7 ****
12 weeks deviated-injected nondeviated-injected 3.35 × 10−4 ***
(* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
Similar, but more prominent, pairwise differences were noted among bulkiest height changes.
Significant difference was present between most of the groups at all time points except between controls
and a few groups at 4 and 8 weeks. The bulkiest height change was significantly different within all
groups at 12 weeks (Table 5).
2.6. Summary
In brief, the volume and bulkiest height on the BoNT injected side decreased over time in both
types of asymmetry. The reductions in volume and bulkiest height by BoNT were significantly greater
in the non-deviated chin group than in the group with chin deviation (Figures 1 and 2).
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Table 5. Pairwise comparisons between group levels for bulkiest height change. Pairwise t-test.
Time Group1 Group2 Bonferroni-Adjusted p-Value
4 weeks deviated-control nondeviated-control 1.00
4 weeks deviated-control deviated-injected 2.30 × 10−2 *
4 weeks deviated-control nondeviated-injected 1.62 × 10−6 ****
4 weeks nondeviated-control deviated-injected 3.83 × 10−1
4 weeks nondeviated-control nondeviated-injected 4.29 × 10−5 ****
4 weeks deviated-injected nondeviated-injected 7.93 × 10−3 **
8 weeks deviated-control nondeviated-control 1.00
8 weeks deviated-control deviated-injected 2.99 × 10−3 **
8 weeks deviated-control nondeviated-injected 4.23 × 10−8 ****
8 weeks nondeviated-control deviated-injected 5.16 × 10−2
8 weeks nondeviated-control nondeviated-injected 6.94 × 10−7 ****
8 weeks deviated-injected nondeviated-injected 1.40 × 10−3 **
12 weeks deviated-control nondeviated-control 2.83 × 10−1
12 weeks deviated-control deviated-injected 1.97 × 10−5 ****
12 weeks deviated-control nondeviated-injected 2.01 × 10−12 ****
12 weeks nondeviated-control deviated-injected 5.49 × 10−3 **
12 weeks nondeviated-control nondeviated-injected 1.27 × 10−10 ****
12 weeks deviated-injected nondeviated-injected 7.98 × 10−07 ****
(* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001).
3. Discussion
The etiology of each type of facial asymmetry may differ, each requiring appropriate plans for
optimal outcomes. Likewise, it can be assumed that the effect of BoNT may differ according to the
facial asymmetry characteristics. The etiology of a deviated chin is believed to be asymmetric growth
of the condyle or the entire mandible [11]. Given the several analyses and classifications of facial
asymmetry based on different etiologic factors, it can be assumed that the effect of BoNT may vary
depending on the etiology of the facial asymmetry [1,12].
Several tools are used for the diagnosis and classification of facial asymmetry. Posteroanterior
(PA) cephalography provides information about diagnostic structures and is easy to perform while also
being low-cost. For these reasons, PA cephalography has long been useful for diagnosis and planning;
even in the era of 3D analysis, its reliability and validity has been well-established [1,13,14].
The skeletal midsagittal reference line (MSR) was established from the crista galli, vertically
through the anterior nasal spine and extended inferiorly beneath the chin; this method is known
to be highly reproducible [13]. Deviation of the menton in particular, which is located at the most
inferior region of the mandible, is the most likely cause of perceived facial asymmetry [10,15]. We thus
selected the menton as a reference point for measurements of facial asymmetry and then classified the
findings into two types according to the degree of deviation of the menton from the MSR based on PA
cephalograms. Approximately 3 to 4 mm of deviation is reported to be the perceivable threshold and
is thus considered clinically significant [16].
There has been a steady demand for the treatment of facial asymmetries in even the mildest
amount. Demand for non-surgical or less invasive means also exists. BoNT therapy is a relatively
simple and aesthetically effective treatment for facial asymmetry by means of reducing the volume of
the masseter muscle [8]. Previous studies have reported the efficacy of BoNT for facial asymmetry.
Shim et al. reported the volume and width of the lower face decreases significantly after 4, 8, 12,
and 24 weeks [3]. Kim et al. reported that the majority patients who underwent BoNT injection for
the purpose of lower face contouring were satisfied with the results [17]. Since its introduction for
cosmetic use in 1994, specifically for the treatment of masseteric hypertrophy, there have been many
clinical studies into the efficacy of BoNT treatment using photography, ultrasonography, and computed
tomography (CT) as analysis tools [3].
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However, recently developed tools such as three-dimensional (3D) laser scanning are now being
used to evaluate the efficacy of BoNT, since they allow for the accurate measurement of changes in the
external facial contours [18]. The technology also allows the change in facial appearance to be readily
demonstrated to both patients and clinicians. The laser scan provides more accurate measurements of
the facial contours compared to other analysis tools [18,19].
As facial asymmetry itself is a three-dimensional matter, a two-dimensional measure may be
insufficient when analyzing it with PA cephalograms. However, even defining the midline of face
and facial asymmetry itself becomes more complex in a three-dimensional setting, as witnessed by
the increasing number of studies published over recent decades [1,14,15,20–22]. Considering that
the perception of asymmetry is subjective rather than analytic in a real-life setting, the powerful
criteria of menton deviation in a two-dimensional cephalogram may still be useful for research
purposes [20]. In this study, the changes in volume and bulkiest height were measured by 3D laser
scanning, and differences obtained by subtracting after superimposition yielded accurate results.
After the onset of BoNT-induced muscle atrophy, new neuromuscular synapses may form as a
result of sprouting of pre-synaptic axons, resulting in muscle recovery [7]. A better understanding of
the effect of BoNT will require follow-up of any resulting change in the volume and bulkiest height
for a minimum of 12 months. In addition, the degree of recovery may differ according to the type of
facial asymmetry.
While lateral changes following orthognathic surgery are relatively easy to predict, precise prediction
of postoperative symmetry remains challenging, despite patient expectation [1]. Soft-tissue thickness
is known to camouflage hard-tissue asymmetry, so the actual skeletal asymmetry may be greater than
that seen in the patient’s face [1]. Similarly, soft-tissue change is known to compensate for hard-tissue
changes in the frontal plane, which may make the quantitative prediction of soft tissue changes more
difficult, resulting in post-surgery asymmetry [23]. In such cases, this study suggests that BoNT
might be considered as an adjunctive measure to reduce the more prominent side for the resolution of
transverse asymmetry of the lower face.
4. Conclusions
BoNT significantly reduced the soft-tissue volume and height of the lower face over a 12 week
time period. The reduction was significantly more effective in cases without chin deviation. Therefore,
BoNT injection can be considered for the resolution of transverse asymmetry of the lower face by
means of reducing the prominent side, especially in cases without chin deviation.
5. Materials and Methods
5.1. Patients
Sixteen volunteers aged 20 and older, complaining of an asymmetric lower face, were enrolled in
this study. Exclusion criteria were pregnancy, history of drug allergy, and any other systemic illnesses.
Informed consent was obtained from all of the volunteers, who were advised of their freedom to
withdraw from the study at any time. The study was approved by the Yonsei University Dental
Hospital Institutional Review Board (IRB No. 2-2015-0037) on 17 September 2015.
5.2. Facial Asymmetry and Group
The facial asymmetry of each patient was assessed using posteroanterior (PA) cephalography
taken before the injection in all subjects. The skeletal midsagittal reference (MSR) line was established
from the crista galli (Cg), vertically through the anterior nasal spine (ANS) and extended inferiorly
beneath the chin; this method is known to be highly reproducible [13]. Deviation of the menton (Me),
the most inferior point of the chin, is thought to be the lead cause of perceived facial asymmetry [15]
(Figure 3).
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Patients were divi ed into two groups based on t tent of ME deviation. The first group was
with a deviated chin, defined by Me deviation of 3 mm or more. The other showed e deviation of less
than 3 mm, below the threshold of clinical significance and thus considered a non-deviated chin [16].
5.3. BoNT Injection
A total of 25 U of BoNT type A was injected into the unilateral masseter muscle of the prominent
side for each participant using a 1 mL syringe with a 29-gauge, 1/2-inch-long needle. The BoNT was
injected into two points 1 cm apart at the center of the lower one-third of the identified masseter muscle,
which is kno n to be the safest and most efficient injection site for BoNT. The uninjected contralateral
side was assigned as a control for each group.
5.4. Measur ment
The effect of BoNT was evaluated by measurin t e c anges in the volume and bulkiest eight
of the lower face on each side with a 3D laser scan using the Vivid 9i laser scanner (Minolta, Tokyo,
Japan). The 3D laser scan was conducted at four time points: before the injection and 4, 8, and 12 weeks
thereafter. A single technical expert performed all the scans, and all images were merged into single
3D facial images using image analysis software (Rapidform 2004, Inus Technology, Seoul, Korea).
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The border of the lower face was delineated using the following reference points: ala; cheilion; labral
inferior; soft-tissue pogonion; soft-tissue menton; soft-tissue gonion and tragion. Differences in the
volume and bulkiest height of the lower face were measured by superimposition of the data obtained
over time.
5.5. Statistical Analyses
Mann–Whitney U test and Fisher’s exact test was used for comparing demographic factors of study
objects. A two-way mixed measures analysis of variance (ANOVA) with Bonferroni correction was used
to compare the means of three groups cross-classified by two independent variables: a between-subjects
factor, group, and a within-subjects factor, time. Post-hoc tests were done using one-way ANOVA
for simple main effect and pairwise independent t-tests for simple pairwise comparisons. Statistical
significance was considered at the level of 0.05. Statistical analyses were performed using the R
programming language (R Core Team, Vienna, Austria, 2020) [24].
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